A study comparing Effectiveness of oral Diclofenac Sodium versus a nutraceutical combination in posterior heel pain

A randomised contol trial comparing effectiveness of oral Diclofenac sodium versus combination of collagen peptide type-1,chondroitin sulphate,sodium hyluronate and vitamin-C in achilles tendinopathy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/06/026230

Enrollment

Registered

2020-06-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M766- Achilles tendinitis

Interventions

Intervention1: Study group will receive a combination of collagen peptide type-1 (40mg), chondroitin sulphate (200mg), sodium hyluronate (30mg) and vitamin-c (35mg) in a dose of 1TDS (thrice in a day)

Eligibility

Inclusion criteria

Inclusion criteria: 1.Aged 18 years or over of either gender. 2.Patient diagnosed clinically and confirmed by usg, with unilateral or bilateral Achilles tendinopathy of any duration. 3.Physical examination revealing maximum tenderness at the attachment of achilles tendon on the posterior aspect of the calcaneus or anywhere along itâ??s entire length. 4.Patients who are willing to come for follow up.

Exclusion criteria

Exclusion criteria: 1.Less that 18 yrs of age and complete rupture of achilles tendon. 2.Any local trauma or infection and retro calcaneal bursitis alone . 3.Received local steroid injection and any of the similar drug combination of collagen peptide type-1, low molecular weight chondroitin sulphate, sodium hyluronate and vitamin-C within 3month. 4.Diagnosis of vascular insufficiency or neuropathy related posterior heel pain (radiculopathy, tarsal tunnel syndrome) and other causes of posterior heel pain should be ruled out. 5.Hip or ankle instability, excessive weakness, surgery or major trauma and hip or knee replacement. 6.Intra-articular joint injection in the ankle joint within 3 months of the study. 7.Having comorbid conditions like uncontrolled diabetes, chronic renal failure, connective tissue disorders etc. 8.Pregnancy and lactation.

Design outcomes

Primary

Measure	Time frame
1)To find out if combination of collagen peptide type-I, low molecular weight chondroitin sulphate, sodium hyluronate and vitamin-C have any positive outcome in treatment of achilles tendinopathy. 2)To compare outcome of treatment of the two groups, one that will receive combination of collagen peptide type-I, low molecular weight chondroitin sulphate, sodium hyluronate and vitamin-C with Diclofenac sodium group in achilles tendinopathy. Timepoint: Analysis was done just before scheduled submission of thesis i.e.December 2016	—

Measure

Time frame

1)To find out if combination of collagen peptide type-I, low molecular weight chondroitin sulphate, sodium hyluronate and vitamin-C have any positive outcome in treatment of achilles tendinopathy. 2)To compare outcome of treatment of the two groups, one that will receive combination of collagen peptide type-I, low molecular weight chondroitin sulphate, sodium hyluronate and vitamin-C with Diclofenac sodium group in achilles tendinopathy. Timepoint: Analysis was done just before scheduled submission of thesis i.e.December 2016

—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr Arun Kumar Choudhary

All India Institute of Medical Sciences New Delhi

slyaiims@yahoo.co.in9650238890

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026